Acute Monoblastic Leukemia (AmoL) Overview

Save information for later
Sign Up

Learn About Acute Monoblastic Leukemia (AmoL)

View Main Condition: Leukemia

What is the definition of Acute Monoblastic Leukemia (AmoL)?
Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
What are the alternative names for Acute Monoblastic Leukemia (AmoL)?
  • Acute monoblastic leukemia
  • AML M5
  • AML-M5
  • Acute monocytic leukemia
  • Acute myeloblastic leukemia type 5
Who are the top Acute Monoblastic Leukemia (AmoL) Local Doctors?
Daniel A. Pollyea
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Daniel A. Pollyea
Hematology Oncology | Hematology | Oncology
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Daniel A. Pollyea
Hematology Oncology | Hematology | Oncology

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Pollyea is a Hematologist Oncology specialist and a Hematologist in Aurora, Colorado. Dr. Pollyea is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Pollyea is currently accepting new patients.

Marina Y. Konopleva
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Marina Y. Konopleva
Hematology Oncology | Hematology | Oncology
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Marina Y. Konopleva
Hematology Oncology | Hematology | Oncology

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marina Konopleva is a Hematologist Oncology specialist and a Hematologist in Bronx, New York. Dr. Konopleva is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Monoblastic Leukemia (AmoL)
Wanggang T. Zhang
Elite in Acute Monoblastic Leukemia (AmoL)
Wanggang T. Zhang
157 Xiwu Road, 
Xi'an, CN 

Wanggang Zhang practices in Xi'an, China. Zhang is rated as an Elite expert by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Their top areas of expertise are Acute Monoblastic Leukemia (AmoL), Acute Myeloid Leukemia (AML), Leukemia, and Multiple Myeloma.

View All Doctors
What are the latest Acute Monoblastic Leukemia (AmoL) Clinical Trials?
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy
Enrollment Status: Recruiting
Publish Date: November 21, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Who is this study for: Child to adult patients with Acute Lymphocytic Leukemia or Acute Myelogenous Leukemia
Enrollment Status: Recruiting
Publish Date: September 12, 2025
Intervention Type: Radiation, Procedure, Biological, Drug
Study Drugs: Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34-Positive-Enriched and CD45RA-Depleted Peripheral Blood Stem Cells, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cells, Cyclosporine, Sirolimus
Study Phase: Phase 2

Summary: This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may als...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center